FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094075265> ?p ?o ?g. }

• W3094075265 endingPage "e704" @default.
• W3094075265 startingPage "e703" @default.
• W3094075265 abstract "Stereotactic radiosurgery (SRS) confers excellent local control for melanoma brain metastases (MBM). Factors impacting the rate of volumetric regression in the follow-up period, including the nature and timing of systemic therapy, are poorly understood. This study examines the impact of systemic therapy on MRI volumetric tumor response over time of melanoma brain metastases following SRS. A retrospective analysis was performed of patients who received single-fraction Cobalt-based SRS for MBM from January 2016 to June 2019. Predictive factors relating to SRS dose, volume and systemic therapy treatment factors such type (CTLA-4, PD-1 and/or BRAF/MEK inhibitors) and timing were collected. Treatment volume of each lesion was delineated on a T1-weighted Gadolinium contrast enhanced MRI at baseline and follow-up. Cubic spline interpolation was used to impute missing data across time intervals. The primary outcome was relative volumetric change in T1-contrast enhancement at 3, 6, 9, 12- and 15-months relative to baseline. A repeated measures ANOVA was used to assess for differences in mean volumetric change between intervals. A linear mixed multivariate regression analysis was performed to assess the relationship between explanatory variables and volumetric change with a two-tailed significance of α = 0.05. 101 patients with 425 MBM were treated with SRS. Median follow-up was 29.2 months (IQR 19.7-39.8). Median dose, baseline volume and lesion diameter were 20Gy (IQR 18-20), 0.24cc (IQR 0.06-1.02) and 7.7mm (IQR 4.8-12.4). 53% of patients were BRAF mutant. 65% had failed BRAF inhibitors at time of SRS. 34% of patients received BRAF inhibitors concurrently (± 48 hours). 77% of patients received concurrent CTLA-4/PD-1 immunotherapy (2 weeks prior-4 weeks post-SRS). Median interpolated lesion size at 3, 6, 9, 12 and 15-month was 73.6%, 55.4%, 49.7%, 54.2% and 42.5% of baseline respectively. There was a statistically significant decrease in lesion size in the 0-3 and 3-6 month interval (p<0.001). Lesion regression stabilized after 6-months. 89.7% of treated lesions had durable local control on MRI at last follow-up. Patients receiving concurrent immunotherapy had a significantly greater regression in tumor volume at 3-months (37% superior [95% CI 6-68.1%, p = 0.02] and 6-months (48% superior [95% CI 7.4-89.5%, p = 0.02] compared to those commencing >4 weeks post SRS however lesion regression velocity was comparable by 9- and 12-months. A 1mm increase in maximal lesion diameter was associated with a 1.5% (95% CI 0.04-2.9, p = 0.04) and 2% (95% CI 0.4-3.7%, p = 0.016) greater reduction in volume at 3- and 6-months. 5% of patients experienced symptomatic radionecrosis (RN). 19% had non-RT grade 3 or higher toxicity. This study demonstrates a significantly greater volumetric regression with concurrent immunotherapy and SRS in MBM in the initial 6 months post SRS. Combined modality treatment offers excellent local control with low RN specific toxicity." @default.
• W3094075265 created "2020-10-29" @default.
• W3094075265 creator A5002192039 @default.
• W3094075265 creator A5027283261 @default.
• W3094075265 creator A5038521316 @default.
• W3094075265 creator A5050690162 @default.
• W3094075265 creator A5053710234 @default.
• W3094075265 creator A5054723003 @default.
• W3094075265 creator A5054772288 @default.
• W3094075265 creator A5064749442 @default.
• W3094075265 creator A5077898964 @default.
• W3094075265 date "2020-11-01" @default.
• W3094075265 modified "2023-09-25" @default.
• W3094075265 title "Quantitative Volumetric Tumor Response And Toxicity Outcomes In Patients Treated With Combination Stereotactic Radiosurgery (SRS) And Immunotherapy For Melanoma Brain Metastases" @default.
• W3094075265 doi "https://doi.org/10.1016/j.ijrobp.2020.07.062" @default.
• W3094075265 hasPublicationYear "2020" @default.
• W3094075265 type Work @default.
• W3094075265 sameAs 3094075265 @default.
• W3094075265 citedByCount "0" @default.
• W3094075265 crossrefType "journal-article" @default.
• W3094075265 hasAuthorship W3094075265A5002192039 @default.
• W3094075265 hasAuthorship W3094075265A5027283261 @default.
• W3094075265 hasAuthorship W3094075265A5038521316 @default.
• W3094075265 hasAuthorship W3094075265A5050690162 @default.
• W3094075265 hasAuthorship W3094075265A5053710234 @default.
• W3094075265 hasAuthorship W3094075265A5054723003 @default.
• W3094075265 hasAuthorship W3094075265A5054772288 @default.
• W3094075265 hasAuthorship W3094075265A5064749442 @default.
• W3094075265 hasAuthorship W3094075265A5077898964 @default.
• W3094075265 hasBestOaLocation W30940752651 @default.
• W3094075265 hasConcept C126322002 @default.
• W3094075265 hasConcept C126838900 @default.
• W3094075265 hasConcept C141071460 @default.
• W3094075265 hasConcept C143998085 @default.
• W3094075265 hasConcept C187960798 @default.
• W3094075265 hasConcept C2777658100 @default.
• W3094075265 hasConcept C2778120868 @default.
• W3094075265 hasConcept C2780387249 @default.
• W3094075265 hasConcept C2780400711 @default.
• W3094075265 hasConcept C2781156865 @default.
• W3094075265 hasConcept C2781464078 @default.
• W3094075265 hasConcept C2989005 @default.
• W3094075265 hasConcept C38180746 @default.
• W3094075265 hasConcept C44249647 @default.
• W3094075265 hasConcept C500558357 @default.
• W3094075265 hasConcept C502942594 @default.
• W3094075265 hasConcept C509974204 @default.
• W3094075265 hasConcept C71924100 @default.
• W3094075265 hasConceptScore W3094075265C126322002 @default.
• W3094075265 hasConceptScore W3094075265C126838900 @default.
• W3094075265 hasConceptScore W3094075265C141071460 @default.
• W3094075265 hasConceptScore W3094075265C143998085 @default.
• W3094075265 hasConceptScore W3094075265C187960798 @default.
• W3094075265 hasConceptScore W3094075265C2777658100 @default.
• W3094075265 hasConceptScore W3094075265C2778120868 @default.
• W3094075265 hasConceptScore W3094075265C2780387249 @default.
• W3094075265 hasConceptScore W3094075265C2780400711 @default.
• W3094075265 hasConceptScore W3094075265C2781156865 @default.
• W3094075265 hasConceptScore W3094075265C2781464078 @default.
• W3094075265 hasConceptScore W3094075265C2989005 @default.
• W3094075265 hasConceptScore W3094075265C38180746 @default.
• W3094075265 hasConceptScore W3094075265C44249647 @default.
• W3094075265 hasConceptScore W3094075265C500558357 @default.
• W3094075265 hasConceptScore W3094075265C502942594 @default.
• W3094075265 hasConceptScore W3094075265C509974204 @default.
• W3094075265 hasConceptScore W3094075265C71924100 @default.
• W3094075265 hasIssue "3" @default.
• W3094075265 hasLocation W30940752651 @default.
• W3094075265 hasOpenAccess W3094075265 @default.
• W3094075265 hasPrimaryLocation W30940752651 @default.
• W3094075265 hasRelatedWork W1987683595 @default.
• W3094075265 hasRelatedWork W2007536764 @default.
• W3094075265 hasRelatedWork W2089713314 @default.
• W3094075265 hasRelatedWork W2167960661 @default.
• W3094075265 hasRelatedWork W2416310620 @default.
• W3094075265 hasRelatedWork W3031853862 @default.
• W3094075265 hasRelatedWork W3039370264 @default.
• W3094075265 hasRelatedWork W3093795671 @default.
• W3094075265 hasRelatedWork W4283380970 @default.
• W3094075265 hasRelatedWork W4288037168 @default.
• W3094075265 hasVolume "108" @default.
• W3094075265 isParatext "false" @default.
• W3094075265 isRetracted "false" @default.
• W3094075265 magId "3094075265" @default.
• W3094075265 workType "article" @default.